GE HealthCare diagnostic drug to miss annual sales view, shares fall

GE HealthCare Technologies

29/10/2025 18:06

Updates

** GE Healthcare GEHC.O shares fall 1.8% to $77.94

** Medical device maker reports Q3 adjusted profit of $1.07/shr vs analysts' average estimate of $1.05/shr - LSEG data

** However, co says it will fall short of its $30 million annual sales forecast for Flyrcado, its heart disease diagnostic drug launched in March

** "This (share move) seems to be short sighted to us" -Evercore analyst Vijay Kumar

** Management "remains super bullish" on the medium-term opportunity, saying if 25% of the market switches to Flyrcado, it would bring $1 billion in annual sales - Kumar

** GEHC's quarterly revenue of $5.14 billion beats analysts' average expectation of $5.08 billion

** Co raised the lower end of its annual adjusted profit forecast to $4.51/shr from $4.43/shr, keeping the top end at $4.63

** Including session's move, stock down 0.4% YTD

 (Reporting by Sahil Pandey and Puyaan Singh in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))